2025 promises further advancements that will continue to shape ADHD diagnosis, treatment, and support for practitioners as well as individuals across their lifespan.
We spoke with our US-based clinical advisor, Dr Corina Weir, to highlight the emerging trends and breakthroughs expected to shape the ADHD care landscape.
1. Personalized treatment plans
The traditional “one-size-fits-all” ADHD treatment approach is being replaced with personalized clinical workflows. These accommodate individual variability like symptom profiles, life stages, and biological factors. Now, patients have more treatment options and are becoming increasingly involved in the conversation about their own care.
Treatment plans can include a variety of options, including lifestyle modifications, medication, therapy, and other approaches. Systematic reviews highlight the benefits of combined approaches, improving both short- and long-term outcomes in ADHD treatment.
As the upcoming US adult ADHD diagnostic guidelines are released in 2025 (mentioned later in this post), we expect even more emphasis on personalization.
2. Medication response testing
Today, many clinicians are still relying on trial-and-error prescribing when treating ADHD (Cortese, 2023).
According to a survey, on average, children try 2.75 different medications and adults 2.56 prescriptions before finding one that works for them.
Recent studies (Gustafsson & Hansen, 2023; Sanyal et al., 2024) show that individualized medication response testing can minimize trial-and-error prescribing. This leads to faster symptom relief and fewer side effects by targeting the individual's holistic functioning rather than symptoms alone.
Monitoring symptoms after medication has been prescribed can help you make required changes and ensure treatments are personalized for patients.
Subjective rating scales can give you more information on patient progress following medication; however, they have limitations. Objective testing provides data on individual symptoms and allows for easy tracking and monitoring over time.
3. Advancing research on ADHD in girls and women
Girls and women have been historically under-researched, underdiagnosed, and undertreated. Ongoing advocacy, however, has resulted in more focus on this demographic. During ADHD Awareness Month in 2024, the community saw a strong emphasis on females’ unique challenges. Leaders like Professor Sandra Kooij are amplifying the conversation through webinars and research initiatives.
Studies continue to explore how ADHD symptoms manifest differently in females compared to males, often leading to later diagnosis and treatment. New studies are expected to delve deeper into how hormonal shifts exacerbate ADHD symptoms and which tailored interventions can reduce these effects.
💡 Explore our recent webinar on ADHD and women's health to dive deeper into this topic.
This growing awareness has also sparked deeper research into sex-based differences. Particularly hormonal fluctuations and their impact on symptoms across puberty, menstruation, pregnancy, and menopause.
Research by Young et al. (2020) and Dorani et al. (2021) acknowledges the importance of addressing sex differences in the condition, for example during puberty, menstruation, pregnancy, and menopause.
4. APSARD’s long-awaited guidelines for adult ADHD
For US clinicians, a major milestone in 2025 will be the new APSARD guidelines for diagnosing and treating adult ADHD. The absence of formal guidelines has left clinicians navigating a complex care landscape with great difficulty and inconsistency in care.
This long-overdue resource will help elevate the quality of care, especially for practitioners less familiar with the condition.
What to expect from APSARD guidelines
These guidelines will be based on research and tested metrics from the past five years – providing much-needed standardization in the diagnosis and treatment process, offering evidence-based protocols.
They are designed to be accessible to practitioners across specialties, supporting those less familiar with ADHD to introduce and follow robust clinical workflows.
5. ADHD in the DSM-5 and the rise of new subtypes
Digital health tools have become indispensable in ADHD care. According to October 2024 CDC data, nearly 46% of adults with ADHD have used telehealth, especially for prescriptions or therapy.
Since March 2020, around one third of adults with ADHD used telehealth services for prescription of medication or therapy for ADHD. Modernizing and streamlining the diagnostic process ensures efficiency and accuracy which saves both time and money.
These services bridge access gaps, enabling patients in underserved areas to connect with specialists.
Objective ADHD diagnosis and treatment solutions like QbCheck are helping clinicians use a scalable and standardized way to use data-driven testing. Objective ADHD tests offer a consistent and evidence-based measure of ADHD symptoms, supporting clinicians in making data-driven decisions